Eli Lilly experimental obesity drug Retatrutide hits up to 30% weight loss in pivotal trial Eli Lilly (NYSE:LLY) announced historic topline results from its Phase 3 TRIUMPH-1 clinical trial, showing that its next-generation investigational drug, retatrutide, helped adults with obesity or overweight lose an average of up to 30.3% of their body weight
See more comments To view or add a comment, sign in More Relevant Posts We are proud to support #WorldHeartDay
Our mission is to help you embrace a healthier lifestyle through a transparent, science-backed approach
Anti-Aging, Brain Health Support, Memory Support
GHK-Cu as part of a broader longevity protocol is reasonable
This sounds basic, but mechanical breakdown in the mouth reduces the particle size that reaches the stomach